OFFICIAL CORRECTION-UBS, MPM team up on $471 mln cancer fund to speed drug development

ZURICH, April 27 (Reuters) - A $471 million UBS

venture fund aims to generate annual returns "north of 10

percent" for its European and Asian investors by financing new

cancer drugs, helping speed them from the lab to the point where

drug companies buy their rights.

Read more